年度财报
Design Therapeutics(DSGN)03-20 04:25
$Design Therapeutics(DSGN)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-033492 Act: 34 Size: 34 MB 网页链接
简介：Design Therapeutics, Inc.于2017年12月18日根据特拉华州法律成立。他们是一家临床阶段的生物制药公司，开创了新的小分子治疗候选物，称为GeneTACs，旨在用于疾病治疗。某些核苷酸重复扩增疾病，如FA，可导致特异性mRNAs表达降低；在其他疾病，如强直性肌营养不良1型(DM1)、FECD和Huntington病，核苷酸重复扩增可导致毒性基因产物的产生，通常与病理性核病灶有关。他们的基因被设计成选择性地与基因重复序列结合，通过恢复或阻断mRNA转录来调节基因表达，并恢复细胞健康。作为一个平台，他们相信GeneTACs在单基因核苷酸重复序列扩增疾病中具有广泛的潜在适用性。
| 今开：3.55 | 昨收：3.65 |
| 最高：3.785 | 最低：3.51 |
| 涨停价： | 跌停价： |
| 总市值：212418459 |
Design Therapeutics(DSGN)03-20 04:25
$Design Therapeutics(DSGN)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-033492 Act: 34 Size: 34 MB 网页链接
Design Therapeutics(DSGN)03-26 07:15
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009063 Size: 7 KB 网页链接
Design Therapeutics(DSGN)今天 04:45
$Design Therapeutics(DSGN)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-048411 Act: 34 Size: 15 MB 网页链接
Design Therapeutics(DSGN)03-20 04:15
$Design Therapeutics(DSGN)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-033475 Act: 34 Size: 321 KB 网页链接
Design Therapeutics(DSGN)03-26 07:15
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009062 Size: 4 KB 网页链接
Design Therapeutics(DSGN)今天 04:35
$Design Therapeutics(DSGN)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-048385 Act: 34 Size: 1 MB 网页链接
Design Therapeutics(DSGN)02-15 04:05
$Design Therapeutics(DSGN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000929638-24-000641 Act: 34 Size: 148 KB 网页链接
Design Therapeutics(DSGN)今天 04:35
$Design Therapeutics(DSGN)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-048399 Act: 34 Size: 290 KB 网页链接
Design Therapeutics(DSGN)03-21 08:05
$Design Therapeutics(DSGN)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-24-008788 Size: 14 KB 网页链接
Design Therapeutics(DSGN)03-20 04:35
$Design Therapeutics(DSGN)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0000950170-24-033525 Act: 33 Size: 154 KB 网页链接
BT财经2023-08-17 17:45
【BT机构股评】生物制药公司Design Therapeutics股票评级下调
SVB Securities将生物制药公司Design Therapeutics的股票评级从“跑赢大盘”下调至“与大盘持平”，并将其目标价从22美元下调至6美元。此前，该公司公布的DT-216治疗弗里德赖希共济失调（Friedreich's ataxia）的i期MAD研究数...查看全文
薛定锷之猫2023-02-21 06:27
$Design Therapeutics(DSGN)$ 贝壳兄弟在退出？大幅减仓查看全文
anos2021-05-06 15:29
$Design Therapeutics(DSGN)$
Design Therapeutics(DSGN)-基本面介绍 网页链接查看全文
牛唐2021-04-30 22:14
$Design Therapeutics(DSGN)$ 又一个30%的收益，棒棒哒。$蔚来(NIO)$ $百度(BIDU)$查看全文
chuminhua2021-03-28 12:07
3月26日，Design Therapeutics、Edgewise Therapeutics、Ikena Oncology和Universe Pharmaceuticals（大自然药业）都在周五登陆纳斯达克。前三家分别收获了超过1亿美元的资金，其中Design募集了2.4亿美元，Edgewise净赚了1.76亿美元，Ikena则成功募集了1.25亿美元。Universe打入2500万美元。
D...查看全文
$Design Therapeutics(DSGN)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-048411 Act: 34 Size: 15 MB 网页链接
$Design Therapeutics(DSGN)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-048385 Act: 34 Size: 1 MB 网页链接
$Design Therapeutics(DSGN)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-048399 Act: 34 Size: 290 KB 网页链接
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009062 Size: 4 KB 网页链接
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-009063 Size: 7 KB 网页链接
$Design Therapeutics(DSGN)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-24-008788 Size: 14 KB 网页链接
$Design Therapeutics(DSGN)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0000950170-24-033525 Act: 33 Size: 154 KB 网页链接
$Design Therapeutics(DSGN)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-033492 Act: 34 Size: 34 MB 网页链接
$Design Therapeutics(DSGN)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-033475 Act: 34 Size: 321 KB 网页链接
$Design Therapeutics(DSGN)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-023960 Act: 34 Size: 137 KB 网页链接